202 related articles for article (PubMed ID: 15060719)
1. Angiogenesis inhibition by the novel VEGF receptor tyrosine kinase inhibitor, PTK787/ZK222584, causes significant anti-arthritic effects in models of rheumatoid arthritis.
Grosios K; Wood J; Esser R; Raychaudhuri A; Dawson J
Inflamm Res; 2004 Apr; 53(4):133-42. PubMed ID: 15060719
[TBL] [Abstract][Full Text] [Related]
2. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
4. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth.
Hess C; Vuong V; Hegyi I; Riesterer O; Wood J; Fabbro D; Glanzmann C; Bodis S; Pruschy M
Br J Cancer; 2001 Dec; 85(12):2010-6. PubMed ID: 11747347
[TBL] [Abstract][Full Text] [Related]
5. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
[TBL] [Abstract][Full Text] [Related]
6. Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and fractionated irradiation.
Zips D; Krause M; Hessel F; Westphal J; Brüchner K; Eicheler W; Dörfler A; Grenman R; Petersen C; Haberey M; Baumann M
Anticancer Res; 2003; 23(5A):3869-76. PubMed ID: 14666690
[TBL] [Abstract][Full Text] [Related]
7. Impact of adjuvant inhibition of vascular endothelial growth factor receptor tyrosine kinases on tumor growth delay and local tumor control after fractionated irradiation in human squamous cell carcinomas in nude mice.
Zips D; Hessel F; Krause M; Schiefer Y; Hoinkis C; Thames HD; Haberey M; Baumann M
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):908-14. PubMed ID: 15708274
[TBL] [Abstract][Full Text] [Related]
8. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.
Lin B; Podar K; Gupta D; Tai YT; Li S; Weller E; Hideshima T; Lentzsch S; Davies F; Li C; Weisberg E; Schlossman RL; Richardson PG; Griffin JD; Wood J; Munshi NC; Anderson KC
Cancer Res; 2002 Sep; 62(17):5019-26. PubMed ID: 12208756
[TBL] [Abstract][Full Text] [Related]
9. PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization.
Goldbrunner RH; Bendszus M; Wood J; Kiderlen M; Sasaki M; Tonn JC
Neurosurgery; 2004 Aug; 55(2):426-32; discussion 432. PubMed ID: 15271251
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
Lee L; Sharma S; Morgan B; Allegrini P; Schnell C; Brueggen J; Cozens R; Horsfield M; Guenther C; Steward WP; Drevs J; Lebwohl D; Wood J; McSheehy PM
Cancer Chemother Pharmacol; 2006 Jun; 57(6):761-71. PubMed ID: 16172907
[TBL] [Abstract][Full Text] [Related]
11. Enhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition.
Zips D; Eicheler W; Geyer P; Hessel F; Dörfler A; Thames HD; Haberey M; Baumann M
Cancer Res; 2005 Jun; 65(12):5374-9. PubMed ID: 15958586
[TBL] [Abstract][Full Text] [Related]
12. The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade.
Sini P; Wyder L; Schnell C; O'Reilly T; Littlewood A; Brandt R; Hynes NE; Wood J
Clin Cancer Res; 2005 Jun; 11(12):4521-32. PubMed ID: 15958638
[TBL] [Abstract][Full Text] [Related]
13. Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation.
Hos D; Bock F; Dietrich T; Onderka J; Kruse FE; Thierauch KH; Cursiefen C
Invest Ophthalmol Vis Sci; 2008 May; 49(5):1836-42. PubMed ID: 18436817
[TBL] [Abstract][Full Text] [Related]
14. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
15. Additive effect of PTK787/ZK 222584, a potent inhibitor of VEGFR phosphorylation, with Idarubicin in the treatment of acute myeloid leukemia.
Barbarroja N; Torres LA; Luque MJ; Carretero RM; Valverde-Estepa A; Lopez-Sanchez LM; Rodriguez-Ariza A; Velasco F; Torres A; López-Pedrera C
Exp Hematol; 2009 Jun; 37(6):679-91. PubMed ID: 19463770
[TBL] [Abstract][Full Text] [Related]
16. Vegfb gene knockout mice display reduced pathology and synovial angiogenesis in both antigen-induced and collagen-induced models of arthritis.
Mould AW; Tonks ID; Cahill MM; Pettit AR; Thomas R; Hayward NK; Kay GF
Arthritis Rheum; 2003 Sep; 48(9):2660-9. PubMed ID: 13130487
[TBL] [Abstract][Full Text] [Related]
17. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization.
LaMontagne K; Littlewood-Evans A; Schnell C; O'Reilly T; Wyder L; Sanchez T; Probst B; Butler J; Wood A; Liau G; Billy E; Theuer A; Hla T; Wood J
Cancer Res; 2006 Jan; 66(1):221-31. PubMed ID: 16397235
[TBL] [Abstract][Full Text] [Related]
18. Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal study.
Schoenberger J; Grimm D; Kossmehl P; Infanger M; Kurth E; Eilles C
Endocrinology; 2004 Mar; 145(3):1031-8. PubMed ID: 14607854
[TBL] [Abstract][Full Text] [Related]
19. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.
Drevs J; Hofmann I; Hugenschmidt H; Wittig C; Madjar H; Müller M; Wood J; Martiny-Baron G; Unger C; Marmé D
Cancer Res; 2000 Sep; 60(17):4819-24. PubMed ID: 10987292
[TBL] [Abstract][Full Text] [Related]
20. Prostacyclin antagonism reduces pain and inflammation in rodent models of hyperalgesia and chronic arthritis.
Pulichino AM; Rowland S; Wu T; Clark P; Xu D; Mathieu MC; Riendeau D; Audoly LP
J Pharmacol Exp Ther; 2006 Dec; 319(3):1043-50. PubMed ID: 16973887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
